Allied Market Research


Mirna Sequencing And Assay Market

miRNA Sequencing and Assay Market Size, Share, Competitive Landscape and Trend Analysis Report by Product, by Technology and by End User : Global Opportunity Analysis and Industry Forecast, 2023-2032

LS : Diagnostics and Biotech

Select an option
Author's: | Roshan Deshmukh
Publish Date:

Get Sample to Email

miRNA Sequencing and Assay Market Outlook – 2027

The global miRNA sequencing and assay market is expected to grow in the upcoming years, due to the dominance of this technique as compared with other technique, increase in the funding for research in the field of genomics, and decrease in the sequencing cost.

The miRNA sequencing is a technique used to sequence RNA that makes use of next-generation sequencing methods. It is used by researchers to inspect tissue-specific expression patterns, isoforms of miRNAs, and the disease relation as well as to find the uncharacterized miRNA. This method has ability to be a significant tool for diagnostic and prognostics field.

COVID-19 scenario analysis:

Pharmaceutical and biotechnological companies together with governments around the globe are working to combat the COVID-19 outbreak, from supporting the development of vaccines to scheduling medicines supply chain challenges. Around 115 vaccine candidates and other 155 molecules are in the R&D pipeline. Furthermore, the commonly used drugs, such as hydroxychloroquine, have observed huge boost in demand for the management of COVID-19. In addition, increase has been experienced in the demand for COVID-19 management drugs, which is expected to offer potential opportunity for manufacturers of drugs, as many developed countries are short of these drugs. Owing to the growing demand for vaccine and treatment drugs for COVID-19, the pharmaceutical and biotechnology industry is anticipated to witness a substantial growth in the next few years.

Top impacting factors

  • Factors such as increase in the incidence infectious & transferable diseases, innovations made with the help of new technology, and the use of novel techniques to access the sequence of miRNA are expected to boost the growth of the market.
  • Increase in the acceptance for practical sequencing methods, rise in the cancer-affected rate, and developments made in genomic research work are expected to contribute toward the market growth in coming years.
  • Rise in the attention for miRNA biomarker discovery can boost the growth of miRNA sequencing and assay market growth. In addition, factors such as rise in prevalence of neurological diseases and increase in demand for customized medicines are responsible for market growth.
  • However, factors such as issues related with potential artifacts and requirement of high cost infrastructure can restrain the growth of miRNA sequencing and assay market.

New product launch/news

  • In 2019, Interpace Diagnostics announced publication of new data on thyroid test utility, a paper called “Incremental utility of expanded mutation panel when used in combination with MicroRNA classification in indeterminate thyroid nodules.”
  • In 2018, Illumina entered into a partnership with Thermo Fisher scientific to provide Ampliseq technology solutions to customers.
  • In 2018, Illumina Inc. acquired Pacific Biosciences. Illumina acquired the Pacific Biosciences for $1.2B. Pacific Biosciences develops and manufactures genetic sequencing systems to resolve genetically complex problems.

Key benefits of the report:

  • This study presents the analytical depiction of the global miRNA sequencing and assay market along with the current trends and future estimations to determine the investments.
  • The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the miRNA sequencing and assay market share.
  • The current market is quantitatively analyzed to highlight the miRNA sequencing and assay market growth scenario.
  • Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market. 
  • The report provides a detailed miRNA sequencing and assay market analysis based on competitive intensity and how the competition will take shape in coming years. 

Questions answered in the miRNA sequencing and assay market report:

  • Which are the leading players active in miRNA sequencing and assay market?
  • What are the current trends that will influence the market in the next few years?
  • What are the driving factors, restraints, and opportunities of the market?
  • What are the projections for the future that would help in taking further strategic steps?
  • What segments and region will drive the market growth & why?
  • What are the major types of miRNA sequencing kits and platforms?

miRNA Sequencing and Assay Market Report Highlights

Aspects Details
By Product
  • Sequencing Consumables
  • Library Preparation Kits
By Technology
  • Sequencing by Synthesis
  • Nanopore Sequencing
  • Ion Semiconductor Sequencing
  • SOLiD (Sequencing by Oligonucleotide Ligation and Detection)
By End User
  • Clinical Laboratory
  • Life Science Organization
  • Academic & Research Institutes
  • Contract Research Organizations
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (France, Germany, Italy, Spain, UK, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific)
  • LAMEA  (Brazil, South Africa, Saudi Arabia, Rest of LAMEA)
Key Market Players

Perkinelmer. Inc,, Norgen Biotek Corp, Trilink Biotechnologies, QIAGEN,, Thermo Fisher Scientific, Lexogen GmbH, Takara Bio,, Maravai LifeSciences, Illumina,, Oxford Nanopore Technologies,

Related Tags

Loading Table Of Content...

Individual sections of the reports are available for purchase.
Would you like to see a breakdown of prices by section?

miRNA Sequencing and Assay Market

Global Opportunity Analysis and Industry Forecast, 2023-2032